Second-Quarter 2026 Sales and Earnings

Merck & Co., Inc., Rahway, N.J., USA

August 4, 2026

Agenda

Strategy and Business Update
Robert M. Davis
Chairman and Chief Executive Officer

Financial Results and Outlook
Caroline Litchfield
Executive Vice President and Chief Financial Officer

Research Update
Dr. Dean Y. Li
Executive Vice President and President, Research Laboratories

Question & Answer Session

Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA

This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Strategy and Business Update

Robert M. Davis
Chairman and Chief Executive Officer

Accelerating progress toward transformation of portfolio



As presented January 2026

Additional innovative pipeline programs

- sacituzumab tirumotecan[3]
- MK-1406
- ifinatamab deruxtecan[4]
- islatravir / lenacapavir[5]
- remigromig
- tulisokibart
- WINREVAIR (sotatercept-csrk) for injection 45 mg, 60 mg
- Ohtuvayre (ensifentrine) Inhalation Suspension 3 mg/2.5 mL
- ENFLONSIA (clesrovimab-cfor) 105 mg injection
- enlicitide

1. Non-risk adjusted annual sales by the mid 2030s 2. Clinically derisked defined as first successful Phase 3 study in a certain indication to read out according to PCD on ct.gov 3. In collaboration with Kelun Biotech 4. In collaboration with Daiichi Sankyo; FDA PDUFA date October 10, 2026 5. In collaboration with Gilead

Accelerating progress toward transformation of portfolio



Progress since January 2026

Additional innovative pipeline programs

sacituzumab tirumotecan[3]	MK-1406	ifinatamab deruxtecan[4]
POSITIVE TOPLINE		**UNDER REVIEW**
islatravir / lenacapavir[5]	remigromig	tulisokibart
POSITIVE RESULTS		**POSITIVE TOPLINE**

WINREVAIR (sotatercept-csrk) for injection 45 mg, 60 mg

Ohtuvayre (ensifentrine) Inhalation Suspension 3 mg/2.5 mL

ENFLONSIA (clesrovimab-cfor) 105 mg injection

LIPFENDRA (enlicitide) tablets 20 mg

APPROVED

1. Non-risk adjusted annual sales by the mid 2030s 2. Clinically derisked defined as first successful Phase 3 study in a certain indication to read out according to PCD on ct.gov 3. In collaboration with Kelun Biotech 4. In collaboration with Daiichi Sankyo; FDA PDUFA date October 10, 2026 5. In collaboration with Gilead

Q2 Worldwide Sales

$16.6B

+5% nominal
+4% ex-exchange

Strength in **Oncology** and **Animal Health**

Increasing contributions from **new launches**

Achieved significant pipeline and regulatory progress:

Cardiometabolic & Respiratory

- FDA approved **LIPFENDRA** as first and only oral PCSK9i

Oncology

- Received several approvals for **KEYTRUDA** and **KEYTRUDA QLEX** including one in combination with **WELIREG**
- Presented data at **ASCO** from multiple novel candidates and broad oncology portfolio
- Announced positive topline results for **sac-TMT**[1] in certain patients with advanced or recurrent endometrial cancer

Immunology

- Announced positive topline results for **tulisokibart** from induction-only study of Phase 3 **ATLAS-UC**

Infectious Diseases

- Presented data from innovative HIV portfolio at AIDS 2026 including for **islatravir/lenacapavir**[1]

1. In collaboration

Completed strategic acquisition of Terns Pharmaceuticals

- **Science-driven** business development that **strengthens and complements hematology pipeline**
- Adds **MK-4208**, an investigational **next-generation, allosteric TKI** for treatment of certain patients with **chronic myeloid leukemia**
- Potential **best-in-class profile** with opportunity to further **improve depth and duration of response** in certain patients
- **Multibillion dollar commercial opportunity** and **growth driver** in the next decade, **creating shareholder value**

Successfully executing on strategy to broaden and diversify pipeline

2024-25	2026	2027	2028	2029+
WINREVAIR (sotatercept-csrk)	Idvynso doravirine/islatravir	**nemtabrutinib** BTKi	**raludotatug deruxtecan**[2] CDH6 ADC	**calderasib**[3] KRAS G12Ci
CAPVAXIVE Pneumococcal 21-valent Conjugate Vaccine	LIPFENDRA (enlicitide) tablets 20 mg	**MK-1406** zanamivir-Fc conjugate	**opevesostat** CYP11A1i	**patritumab deruxtecan**[2] HER3 ADC
Ohtuvayre (ensifentrine)	**sacituzumab tirumotecan**[1] TROP2 ADC	**alimatravir** NRTI	**MK-8748** Tie2 agonist/VEGFi	**islatravir + ulonivirine** NRTI + NNRTI
ENFLONSIA (clesrovimab-cfor)	**islatravir / lenacapavir**[1] NRTI / capsid inhibitor	**bomedemstat** LSD1i		**intismeran autogene**[4] INT
KEYTRUDA Qlex pembrolizumab + berahyaluronidase alfa-pmph	**tulisokibart** TL1A mAb	**zilovertamab vedotin** ROR1 ADC		**V181** Tetravalent dengue vaccine
	remigromig Wnt agonist			**MK-1045** CD19xCD3 T-cell engager
	ifinatamab deruxtecan[1] B7-H3 ADC			**gocatamig**[2] DLL3 T-cell engager

Pipeline candidates with first-in-class potential

Cardiometabolic & Respiratory | Infectious Disease | Oncology | Immunology | Ophthalmology

Timing represents approval date for marketed products or announced positive topline results, PDUFA date, or earliest Phase 3 primary completion date according to clinicaltrials.gov for pipeline compounds
1. In collaboration 2. In collaboration with Daiichi Sankyo 3. In collaboration with Taiho Astex 4. In collaboration with Moderna

Financial Results and Outlook

Caroline Litchfield
Executive Vice President and
Chief Financial Officer

Q2 growth across human and animal health with increasing contributions from new products

WORLDWIDE SALES[1]

$16.6B

+5% nominal
+4% ex-exchange

Human Health

$14.8B

+5% growth
+4% ex-exchange

Animal Health

$1.8B

+8% growth
+5% ex-exchange



1. Worldwide Sales includes Other Revenue 2. Launch products include WINREVAIR, KEYTRUDA QLEX, CAPVAXIVE, OHTUVAYRE, ENFLONSIA, IDVYNSO, BRAVECTO QUANTUM and NUMELVI

Oncology: KEYTRUDA continues to benefit patients and drive growth

KEYTRUDA family[1] sales of $8.4B increased 4% driven by strong uptake in earlier-stage cancers and robust demand from metastatic indications

- Growth driven by usage in tumors predominantly affecting women, including those with certain breast and cervical cancers
- Increased use of KEYTRUDA in combination with enfortumab vedotin in locally advanced or metastatic urothelial cancer
- KEYTRUDA QLEX sales of $463M in 2Q26 following launch in 3Q25; permanent J-code effective April 1st



Growth rates exclude the impact of foreign exchange 1. KEYTRUDA family includes KEYTRUDA and KEYTRUDA QLEX (available as KEYTRUDA SC in some markets) 2. ~4 percentage points of negative impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market.

Oncology: Continued impact for patients across broad portfolio

WELIREG sales grew 67% driven by continued higher demand in the U.S. and launch uptake in international markets

Lynparza[1] alliance revenue relatively flat compared with prior year

Lenvima[2] alliance revenue grew 6%, primarily due to higher demand in the U.S., partially offset by net price



Growth rates exclude the impact of foreign exchange 1. In collaboration with AstraZeneca 2. In collaboration with Eisai

Vaccines & Infectious Diseases: Impacting lives globally

GARDASIL sales of $1.2B increased 3% driven by higher sales in certain international markets

- In the U.S., sales were flat primarily due to lower demand and timing of CDC purchases, largely offset by price

CAPVAXIVE[1] sales of $184M increased 40% driven by uptake from ongoing launches in certain international markets and higher demand in the U.S.

IDVYNSO[2] progress on access and reimbursement following recent launches in U.S. and Japan





Growth rates exclude the impact of foreign exchange 1. Launched in 3Q24 2. Launched in 2Q26

Cardiometabolic & Respiratory: Continuing to drive benefit for patients with successful ongoing launches

WINREVAIR sales of $588M driven by continued growth in new patient starts and total prescriptions

- In the U.S., ~1,800 new patients prescribed and >34,000 total prescriptions dispensed
- Ex-U.S., making progress with ongoing launches

OHTUVAYRE[1] sales of $204M reflect continued prescription demand

- Benefitted from specialty pharmacy purchase timing, which is expected to unwind in 3Q26



Growth rates exclude the impact of foreign exchange 1. Ohtuvayre was obtained as part of the acquisition of Verona Pharma on October 7, 2025 2. Sales reported by Verona Pharma

Animal Health: Solid growth driven by livestock and companion animal

Animal Health sales increased 5% to $1.8B

- Livestock sales grew 6% driven by higher demand for ruminant and poultry products
- Companion Animal sales grew 5% driven by new product launches



Growth rates exclude the impact of foreign exchange 1. ~3 percentage points of negative impact of foreign exchange due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market

Q2 2026 non-GAAP financial results summary[1]

$ in billions, except LPS / EPS amounts

	Q2 2026	Q2 2025	Change	Change Ex-FX
Sales	$16.6	$15.8	+5%	+4%
Non-GAAP Gross Margin	81.1%	82.2%	-1.1 pts	-1.5 pts
Non-GAAP Operating Expenses[2]	$12.6	$6.6	91%	90%
Non-GAAP Tax Rate	160.3%	15.0%	N/M	N/A
Non-GAAP (Loss) / Earnings Per Share[3,4]	$(0.13)	$2.13	N/M	N/M

1. The company is providing certain 2026 and 2025 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors' understanding of the company's results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management's compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q2 2026 non-GAAP results include a charge of $5.7 billion related to the acquisition of Terns Pharmaceuticals, Inc. (Terns). Q2 2025 non-GAAP results include $200 million charge related to the closing of a license agreement with Jiangsu Hengrui Pharmaceutical Co., Ltd. (Hengrui Pharma). 3. Q2 2026 includes a charge of $2.31 per share related to the acquisition of Terns. Q2 2025 includes a charge of $0.07 per share related to the closing of a license agreement with Hengrui Pharma. 4. Q2 2026 GAAP LPS of $(0.54).

Updated 2026 financial outlook

	Prior Guidance	Updated Guidance	Key Assumptions
Revenue	$65.8B to $67.0B	$66.3B to $67.3B	• Assumes ~1 percentage point positive impact from FX • Now implies +2% to +4% nominal (+1% to +3% ex-FX)
Non-GAAP Gross Margin Rate	~82.0%	~81.0%	• Now includes higher inventory reserves
Non-GAAP Operating Expenses[1]	$36.0B to $36.8B	$42.0B to $42.7B	• Now includes $5.7B charge related to acquisition of Terns
Other (Income) / Expense	~$1.3B of expense	~$1.4B of expense	• Incorporates financing costs related to acquisition of Terns
Tax Rate	~23.5% to 24.5%	~35.0% to 36.0%	• Incorporates impact of non-tax deductible charge for Terns
Shares Outstanding	~2.48B	~2.48B	• Assumes ~$3B of share repurchases
Non-GAAP EPS[1]	$5.04 to $5.16	$2.66 to $2.76	• Incorporates ~$2.31 impact related to upfront charge for acquisition of Terns • Now assumes ~$0.15 positive impact from FX

1. Guidance does not assume additional significant potential business development transactions

Key modeling considerations

OHTUVAYRE

- Expect 3Q to be impacted by unwind of 2Q specialty pharmacy purchases
- Expect investments behind sales force and promotion to drive accelerated growth in 2027

U.S. KEYTRUDA

- Reaching peak penetration in several key indications
- Expect headwind from timing of wholesaler purchases in 3Q

U.S. BRIDION

- Anticipate slower than previously expected sales decline due to lower generic competition

OTHER REVENUE

- Expect 2H26 to be significantly higher than 2H25 driven by revenue hedging program and expected milestone receipt in 4Q

Remain committed to balanced capital allocation strategy

Q2 Spend ($ in billions)[1]



Augmented our pipeline with value-enhancing **business development** while investing in our **pipeline** and **business** as well as returning **cash to shareholders**

1. Reflects quarter spend 2. Reflects R&D excluding Business Development

Research Update

Dr. Dean Y. Li
Executive Vice President and President,
Research Laboratories

LIPFENDRA the first and only approved oral PCSK9i

LIPFENDRA

- **First** FDA-approved **oral PCSK9 inhibitor** to reduce LDL-C in adults with hypercholesterolemia, along with diet and exercise
- ASCVD remains the **leading cause** of **morbidity** and **mortality** worldwide
  - Ongoing CORALreef Outcomes trial evaluating effect of LIPFENDRA on cardiovascular morbidity and mortality
- Currently under review by **EMA** and **China NMPA**
- Approval further validates **macrocyclic peptide platform**
- Evaluating potential **fixed-dose combinations** with **rosuvastatin** and **Lp(a)** (MK-7262)

LIPFENDRA® (enlicitide) tablets 20 mg

*Images not actual size

Advancing innovative longer-acting oral treatment options for people living with HIV

Islatravir/lenacapavir[1]

- Presented **positive results** from Phase 3 **ISLEND-1** and **ISLEND-2** studies demonstrating **ISL/LEN** was effective in adults with virologically suppressed HIV who switched from BIC/FTC/TAF or other oral SoC
- Data support potential for ISL/LEN to be **first once-weekly oral treatment option**

Islatravir/ulonivirine

- Presented positive Phase 2b results for **ISL+ULO** demonstrating maintenance of viral suppression in adults with virologically suppressed HIV who switched from BIC/FTC/TAF
- **Advancing to Phase 3** in new-to-treatment and treatment experienced populations of adults living with HIV

1. In collaboration

Important updates across infectious disease programs

MK-1406

- Phase 3 **ANCHOR study** completed enrollment in Southern Hemisphere
- Plan to enroll second Northern Hemisphere flu season to broaden geographic footprint and support **robust global registration strategy**
- Continue to anticipate potential **approval in 2029**

CAPVAXIVE

- **FDA approved expanded indication** for children and adolescents aged 2 through 17 years who are at increased risk for pneumococcal disease

Important progress in immunology clinical development program

Tulisokibart

- Announced **positive topline results** of induction-only study in moderately to severely active ulcerative colitis
- **First anti-TL1A** mAb to demonstrate **positive results** in a **Phase 3** trial

ATLAS-UC

Study 1	Study 2
~720 patients	**~300 patients**
52-week induction and maintenance	12-week induction-only
Ongoing	**POSITIVE TOPLINE**

PCD: Aug 2026

Broadest TL1A development program

- **Gastroenterology**
- **Dermatology**
- **Rheumatology**

Continuing to advance cancer care with broad, differentiated portfolio and pipeline

Positive topline results

- **KEYNOTE-C93**: Announced study evaluating **KEYTRUDA** monotherapy met primary endpoint of **PFS** for certain patients with advanced or recurrent **endometrial cancer** with dMMR tumors versus platinum doublet chemotherapy
- **TroFuse-005**: Announced study evaluating **sac-TMT**[1] met primary endpoints of **OS** and **PFS** in patients with advanced or recurrent **endometrial cancer** who have progressed after platinum-based chemotherapy and anti-PD-1/L1
  - **First TROP2 ADC** to **improve OS and PFS** compared to chemotherapy in certain patients with advanced or recurrent endometrial cancer
  - **First positive readout** from 17 **global Phase 3 TroFuse studies**

Recent approvals

- **KEYNOTE-905**[1]: EC approved KEYTRUDA with enfortumab vedotin as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment for resectable cis-ineligible MIBC
- **KEYNOTE-D19**[1]: FDA approved KEYTRUDA and KEYTRUDA QLEX each with sacituzumab govitecan for 1L treatment of PD-L1 positive (CPS ≥ 10) unresectable locally advanced or metastatic TNBC
- **KEYNOTE-B15**[1]: FDA approved KEYTRUDA and KEYTRUDA QLEX each with enfortumab vedotin-ejfv as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment for the treatment of MIBC
- **LITESPARK-022**: FDA approved KEYTRUDA and KEYTRUDA QLEX each with WELIREG for adjuvant treatment of certain patients with clear cell RCC
  - **13** KEYTRUDA-based regimens now approved in **earlier stage cancer**

1. In collaboration

Significant late-stage pipeline milestones expected over next six months

Cardiometabolic & respiratory

WINREVAIR

- HYPERION PDUFA date September 21st

Immunology

Tulisokibart

- PCD in August for Phase 3 ATLAS trial in UC
- Presentation of detailed findings from Phase 2 study in HS

Ophthalmology

Remigromig (MK-3000)

- PCD in September for Phase 3 BRUNELLO trial in DME

Oncology

WELIREG

- LITESPARK-011 PDUFA date October 4th

I-DXd[1]

- IDeate-Lung01 PDUFA date October 10th

Sac-TMT[1]

- Presentation of detailed findings from Phase 3 TroFuse-005 trial

ESMO Investor Event

- Monday, October 26th at 6 p.m. CET / 1 p.m. ET

1. In collaboration

Q&A

Robert M. Davis
Chairman and Chief Executive Officer

Caroline Litchfield
Executive Vice President and Chief Financial Officer

Dr. Dean Y. Li
Executive Vice President and President, Research Laboratories

Peter Dannenbaum
Senior Vice President, Investor Relations

Appendix

Q2 2026 GAAP financial results summary

$ in billions, except LPS / EPS amounts

	Q2 2026	Q2 2025	Change	Change Ex-FX
Sales	$16.6	$15.8	+5%	+4%
Operating Expenses (SG&A and R&D)[1,2]	$12.6	$6.7	89%	88%
Tax Rate	-95.9%	11.4%	N/M	N/A
GAAP (Loss) / Earnings per Share[1,2]	$(0.54)	$1.76	N/M	N/M

1. Q2 2026 GAAP results include a charge of $5.7 billion, or $2.31 negative EPS impact, related to the acquisition of Terns 2. 2Q25 GAAP results include $200 million charge, or $0.07 negative EPS impact, related to the closing of a license agreement with Hengrui Pharma

Executing upon balanced capital allocation strategy

Over the past 12 months



Capital investments

2026 to 2030

~$19B

Over 5 years, including more than $14B in the U.S.

Well-positioned balance sheet with capacity to fund **additional value-enhancing business development** opportunities

Committed to the dividend



1. Reflects R&D excluding Business Development 2. Includes BD payments reflected in operating cash flow

Broad and innovative pipeline to address significant unmet medical needs

Phase 2

Oncology

MK-1022 (patritumab deruxtecan)[1]
Biliary
Bladder
Cervical
Endometrial
Esophageal
Gastric
HCC
Melanoma
NSCLC
Ovarian
Pancreatic
Prostate

MK-1045
Hematological Malignancies

MK-1084 (calderasib)[1]
Solid Tumors

MK-2400 (ifinatamab deruxtecan)[1]
Biliary
Bladder
Breast
Cervical
Endometrial
HCC
HNSCC
Melanoma
NSCLC
Ovarian
Pancreatic
Solid Tumors

MK-2870 (sacituzumab tirumotecan)[1]
Biliary
Esophageal
Neoplasm Malignant
Pancreatic

MK-3120
Bladder

KEYTRUDA (MK-3475)
Prostate

KEYTRUDA QLEX (MK-3475A)
Hematological Malignancies (U.S.)

MK-5684 (opevesostat)
Breast
Endometrial
Ovarian

MK-5909 (raludotatug deruxtecan)[1]
Cervical
Endometrial
Gastric
NSCLC
RCC
SCLC

MK-6070 (gocatamig)[1]
SCLC

WELIREG (MK-6482)
Breast

V940 (intismeran autogene)[1]
Bladder
RCC

Neuroscience

MK-2214
Alzheimer's Disease

Cardiometabolic & Respiratory

MK-5475 (frespaciguat)
PH-COPD

MK-5884A (ensifentrine + glycopyrrolate)
COPD

MK-6024 (efinopegdutide)
MASH

MK-7262
Atherosclerosis

WINREVAIR (MK-7962)
Pulmonary Hypertension due to Left Heart Disease

Immunology

MK-7240 (tulisokibart)
Axial Spondyloarthritis
Hidradenitis Suppurativa
Psoriatic Arthritis
Rheumatoid Arthritis
Systemic Sclerosis

MK-8690
Ulcerative Colitis

Infectious Diseases

MK-8591B (islatravir + ulonivirine)
HIV-1 Infection

Phase 3

Oncology

MK-1022 (patritumab deruxtecan)[1]
Breast

MK-1026 (nemtabrutinib)
Hematological Malignancies

MK-1084 (calderasib)[1]
CRC
NSCLC

MK-2140 (zilovertamab vedotin)
Hematological Malignancies

MK-2400 (ifinatamab deruxtecan)[1]
Esophageal
Prostate
SCLC (EU)

MK-2870 (sacituzumab tirumotecan)[1]
Bladder
Breast
Cervical
Endometrial
Gastric
NSCLC
Ovarian

KEYTRUDA (MK-3475)
SCLC

MK-3543 (bomedemstat)
Myeloproliferative Disorders

MK-5684 (opevesostat)
Prostate

MK-5909 (raludotatug deruxtecan)[1]
Ovarian

LYNPARZA (MK-7339)[1]
NSCLC
SCLC

V940 (intismeran autogene)[1]
Melanoma
NSCLC

Ophthalmology

MK-3000 (remigromig)[4]
Diabetic Macular Edema

MK-8748[4]
Neovascular Age-Related Macular Degeneration

Immunology

MK-7240 (tulisokibart)
Crohn's Disease
Ulcerative Colitis

Infectious Diseases

MK-1406
Influenza

LAGEVRIO (MK-4482)[1,3]
COVID-19 (U.S.)

MK-8527 (alimatravir)
HIV-1 PrEP

MK-8591D (islatravir + lenacapavir)[1,2]
HIV-1 Infection

Vaccines

V181
Dengue Fever Virus

Under regulatory review

Oncology

MK-2400 (ifinatamab deruxtecan)[1]
Previously Treated Extensive-Stage SCLC (U.S.)

KEYTRUDA (MK-3475)
Cisplatin Eligible MIBC (EU, JPN)
Cisplatin Ineligible MIBC (JPN)
Newly Diagnosed High-Risk Endometrial (EU)
Platinum-Resistant Recurrent Ovarian (JPN)

WELIREG (MK-6482)
Clear Cell RCC Following Nephrectomy (EU)[5]
Previously Treated Advanced RCC (U.S., EU, JPN)[1,6]

Cardiometabolic & Respiratory

LIPFENDRA (MK-0616)
Primary Hypercholesterolemia or Mixed Dyslipidemia (EU)

WINREVAIR (MK-7962)
Pulmonary arterial hypertension (U.S.)

Infectious Diseases

IDVYNSO (MK-8591A)
HIV-1 Infection (EU)

As of August 4, 2026

1. Being developed in a collaboration 2. On FDA partial clinical hold for higher doses of islatravir than those used in current clinical trials 3. Available in the U.S. under Emergency Use Authorization, which will terminate effective June 29, 2027 4. Program is in Phase 2/3 studies 5. Under review for combination use with KEYTRUDA 6. Under review in Japan for Lenvima, used in combination with WELIREG

Acronyms

ADC = Antibody-drug conjugate

ASCO = American Society of Clinical Oncology

ASCVD = Atherosclerotic cardiovascular disease

B7-H3 = B7 homolog 3

BIC/FTC/TAF = bictegravir/emtricitabine/tenofovir alafenamide

BTKi = Bruton Tyrosine Kinase inhibitor

CDH6 = Cadherin-6

COPD = Chronic obstructive pulmonary disease

CPS = Combined positive score

CRC = Colorectal cancer

CYP11A1 = Cytochrome P450 Family 11 Subfamily A Member 1

DLL3 = Delta-like ligand 3

dMMR = Deficient DNA mismatch repair

DME = Diabetic macular edema

EC = European Commission

EMA = European Medicines Agency

ESMO = European Society for Medical Oncology

HCC = Hepatocellular carcinoma

HER3 = Human epidermal growth factor receptor 3

HIV-1 = Human Immunodeficiency Virus Type 1

HNSCC = Head and neck squamous cell carcinoma

I-DXd = Ifinatamab deruxtecan

INT = Individualized neoantigen therapy

ISL = islatravir

KRAS = Kirsten rat sarcoma viral oncogene homolog

LDL-C = Low-density lipoprotein cholesterol

LEN = lenacapavir

Lp(a) = Lipoprotein(a)

LSD1 = Lysine specific demethylase 1

mAb = Monoclonal antibody

MASH = Metabolic Dysfunction-Associated Steatohepatitis

MIBC = Muscle invasive bladder cancer

NSCLC = Non-small cell lung cancer

NMPA = National Medical Products Administration

NRTI = Nucleoside reverse transcriptase inhibitor

NNRTI = Non-nucleoside reverse transcriptase inhibitor

OS = Overall survival

PCD = Primary completion date

PCSK9 = Proprotein convertase subtilisin/Kexin type 9

PD-1/PD-L1 = Programmed cell death protein-1/Programmed cell death ligand-1

PDUFA = Prescription Drug User Fee Act

PFS = Progression free survival

RCC = Renal cell carcinoma

ROR1 = Receptor tyrosine kinase-like orphan receptor 1

SCLC = Small cell lung cancer

SoC = Standard of care

TIE2 = Tyrosine kinase with immunoglobulin-like and EGF-like domains 2

TKI = Tyrosine kinase inhibitor

TL1A = Tumor Necrosis Factor-like Ligand 1A

TNBC = Triple negative breast cancer

TROP2 = Trophoblast cell surface antigen-2

UC = Ulcerative colitis

ULO = ulonivirine

VEGF = Vascular endothelial growth factor